Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Net Margin (2022 - 2025)

Axsome Therapeutics' Net Margin history spans 4 years, with the latest figure at 14.61% for Q4 2025.

  • For Q4 2025, Net Margin rose 4847.0% year-over-year to 14.61%; the TTM value through Dec 2025 reached 28.69%, up 4577.0%, while the annual FY2025 figure was 28.69%, 4577.0% up from the prior year.
  • Net Margin for Q4 2025 was 14.61% at Axsome Therapeutics, up from 27.6% in the prior quarter.
  • Across five years, Net Margin topped out at 11.88% in Q1 2023 and bottomed at 469.82% in Q2 2022.
  • The 4-year median for Net Margin is 77.05% (2024), against an average of 110.88%.
  • The largest annual shift saw Net Margin soared 32603bps in 2023 before it tumbled -7926bps in 2024.
  • A 4-year view of Net Margin shows it stood at 251.29% in 2022, then soared by 45bps to 137.95% in 2023, then skyrocketed by 54bps to 63.08% in 2024, then soared by 77bps to 14.61% in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Net Margin are 14.61% (Q4 2025), 27.6% (Q3 2025), and 31.97% (Q2 2025).